CD274 and prostate carcinoma: High levels of PD-L1 have been observed in cisplatin-resistant small-cell lung carcinoma cells and enzalutamide-resistant prostate cancer cells36, suggesting the need for further investigation into the effects of rapamycin and other anticancer drugs on resistant cancer cells.